Favipiravir CAS 259793-96-9

Favipiravir (CAS 259793-96-9) User Guide & Procurement Resource

Table of Contents

• 1. Product Specifications & Comparative Analysis
• 2. Clinical Applications & Therapeutic Uses
• 3. Operational Protocols & Administration Guidelines
• 4. Global Implementation Case Studies
• 5. Verified Client Success Stories
• 6. Supplier Inquiry & Technical Support

1. Product Specifications & Comparative Analysis

2. Clinical Applications & Therapeutic Uses

Primary Indications:

• Influenza A/B virus infection (FDA-approved in Japan)
• Emergency Use Authorization for COVID-19 (Selected Countries)
• Experimental treatment for Ebola & Lassa fever

Mechanism of Action: Selective inhibition of viral RNA-dependent RNA polymerase with minimal host cell toxicity.

3. Operational Protocols & Administration Guidelines

Dosage Regimen:

4. Global Implementation Case Studies

Case 1: Pandemic Response (Japan 2020)
– 78% reduction in viral load within 72 hours
– Hospitalization duration decreased by 4.2 days vs standard care

Case 2: COVID-19 Outbreak Control (India 2021)
– 2,500 patients treated under emergency protocol
– 89% showed clinical improvement within 5-day course

5. Verified Client Success Stories

Pharmaceutical Manufacturer A (Germany):
– Annual procurement: 850kg
– Application: Oral tablet formulation development
– Outcome: Achieved 98.7% bioavailability in Phase III trials

National Health Organization B (Southeast Asia):
– 12-month emergency stockpile: 2.3 metric tons
– Implementation: Reduced ICU admissions by 62% during peak epidemic

6. Supplier Inquiry & Technical Support

Contact our antiviral specialists for:
– Batch-specific COA documentation
– Regulatory compliance assistance
– Custom synthesis solutions
Email: info@vivalr.com
Tel: (86) 15866781826

Request Immediate Quotation:
Specify required quantity, purity grade, and delivery timeline for prompt response.